APW
MRNA icon

Allied Private Wealth’s Moderna MRNA Stock Holding History

Allied Private Wealth’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.4K Buy
+412
New +$21.3K 0.02% 319

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Allied Private Wealth's MRNA Position: Q2 2026 in Review

Allied Private Wealth opened a new position in Moderna (MRNA) in Q2 2026: 412 shares worth $30.4K. The stake represents 0.02% of the portfolio and ranks #319 among its holdings.

780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Allied Private Wealth held 412 shares of Moderna worth $30.4K as of Q2 2026.
  • Moderna was a new Allied Private Wealth position in Q2 2026.
  • Moderna made up 0.02% of Allied Private Wealth's portfolio in Q2 2026, its #319 holding.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Allied Private Wealth's 13F filing for Q2 2026, filed 9 Jul 2026.